熱門(mén)詞： 進(jìn)口電動(dòng)溫度調(diào)節(jié)閥結(jié)構(gòu)圖|進(jìn)口電動(dòng)溫度調(diào)節(jié)閥數(shù)據(jù)表進(jìn)口電動(dòng)高溫調(diào)節(jié)閥-德國(guó)進(jìn)口電動(dòng)高溫法蘭調(diào)節(jié)閥進(jìn)口電動(dòng)蒸汽調(diào)節(jié)閥-德國(guó)進(jìn)口電動(dòng)蒸汽調(diào)節(jié)閥
熱門(mén)詞： 進(jìn)口電動(dòng)溫度調(diào)節(jié)閥結(jié)構(gòu)圖|進(jìn)口電動(dòng)溫度調(diào)節(jié)閥數(shù)據(jù)表進(jìn)口電動(dòng)高溫調(diào)節(jié)閥-德國(guó)進(jìn)口電動(dòng)高溫法蘭調(diào)節(jié)閥進(jìn)口電動(dòng)蒸汽調(diào)節(jié)閥-德國(guó)進(jìn)口電動(dòng)蒸汽調(diào)節(jié)閥
AMAG Pharma 美國(guó)AMAG Pharma
美國(guó)AMAG制藥公司是一家生物制藥公司，它在開(kāi)發(fā)和推廣缺鐵性貧血上擁有專(zhuān)有的納米技術(shù)，并且在診斷癌癥和心血管疾病上擁有新型顯像劑技術(shù)。Ferumoxytol 是該公司的主要產(chǎn)品，它是一種靜脈補(bǔ)鐵制劑，用于治療慢性腎病患者的缺鐵性貧血。
Core Technology of AMAG Pharmaceuticals, Inc.
Our core technology is based on the characteristic properties of ultra small, semi synthetic coated iron oxide particles. Our core competencies include the ability to design such particles for particular applications, to manufacture the particles in controlled sizes and to cover the particles with different coatings depending upon the application for which they will be used.
Our iron oxide particles are composed of bioavailable iron that is easily absorbed by the body and incorporated into the body's iron stores. As a result, products using our core technology are well suited for use in intravenous iron replacement therapy.
Iron - A Critical Element in the Body
Iron is critical to a number of processes in the human body and is a key component of the hemoglobin molecule where it serves a vital role in oxygen transport from the lungs to tissues. Low levels of iron in the body is known as iron deficiency and can result in anemia and inadequate oxygen delivery to different organs. Iron deficiency anemia can result when there is an inadequate amount of hemoglobin in red blood cells. Iron deficiency anemia is associated with a number of symptoms including fatigue, lethargy, poor concentration, shortness of breath, palpitations, and dizziness. Low levels of red blood cells can occur because of iron deficiency anemia, blood loss, and/or decreased production of the hormone erythropoietin. Intravenous iron replacement therapy plays a major role, along with erythropoietic stimulating agents, in treating certain types of chronic anemia in patients suffering from chronic kidney disease. Iron deficiency anemia is also common in patients with other conditions and diseases such as abnormal uterine bleeding, cancer and gastrointestinal diseases.
知識(shí)產(chǎn)權(quán)侵權(quán)投訴：不生產(chǎn)任何產(chǎn)品所有產(chǎn)品均來(lái)自產(chǎn)品的生產(chǎn)廠商、代理商、經(jīng)銷(xiāo)商，如有侵權(quán)請(qǐng)聯(lián)系：400-006-7520 ，我們會(huì)在第一時(shí)間處理
本網(wǎng)站所有產(chǎn)品與藥品無(wú)關(guān)
滬公網(wǎng)安備31011502016460號(hào)
